In the last trading session, 1.38 million shares of the Bicara Therapeutics Inc (NASDAQ:BCAX) were traded. Most recently the company’s share price was $13.03, and it changed around -$0.77 or -5.58% from the last close, which brings the market valuation of the company to $709.04M. BCAX currently trades at a discount to its 52-week high of $28.09, offering almost -115.58% off that amount. The share price’s 52-week low was $11.10, which indicates that the current value has risen by an impressive 14.81% since then. We note from Bicara Therapeutics Inc’s average daily trading volume that its 10-day average is 0.82 million shares, with the 3-month average coming to 428.66K.
Bicara Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended BCAX as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Bicara Therapeutics Inc is expected to report earnings per share of -0.28 for the current quarter.
Bicara Therapeutics Inc (NASDAQ:BCAX) trade information
Instantly BCAX has showed a red trend with a performance of -5.58% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 14.28 on recent trading dayincreased the stock’s daily price by 8.75%. The company’s shares are currently down -25.20% year-to-date, but still up 4.74% over the last five days. On the other hand, Bicara Therapeutics Inc (NASDAQ:BCAX) is 0.39% up in the 30-day period. We can see from the shorts that 5.61 million shares have been sold at a short interest cover period of 15.48 day(s).
The consensus price target as assigned by Wall Street analysts is $35, which translates to bulls needing to increase their stock price by 62.77% from its current value. Analyst projections state that BCAX is forecast to be at a low of $35 and a high of $35.
Bicara Therapeutics Inc earnings are expected to increase by 16.24% in 2025, but the outlook is negative -9.13% per year for the next five years.
BCAX Dividends
Bicara Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-11.
Bicara Therapeutics Inc (NASDAQ:BCAX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.43% of Bicara Therapeutics Inc shares, and 86.06% of them are in the hands of institutional investors. The stock currently has a share float of 86.43%.
Vanguard Total Stock Market Index Fund and T. Rowe Price New Horizons Fund, Inc. were the top two Mutual Funds as of Dec 31, 2024 . The former held 636.55 shares worth $8.29 million, making up 1.17% of all outstanding shares. On the other hand, T. Rowe Price New Horizons Fund, Inc. held roughly 589.03 shares worth around $7.68 million, which represents about 1.08% of the total shares outstanding.
